Clinical trials: Progressive Ophthalmoplegia
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Registry
With the increase in life expectancy of our population due to advancement of medical diagnosis and treatments, the incidence of age dependent neurodegenerative diseases increased, including Alzheimer's disease (AD), parkinsonian…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NDD Registry (NCT04472130)
- Where
- Hong Kong
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Vincent Mok
Parkinson's Disease, Parkinsonian Disorders
Gait Analysis in Neurological Disease
The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with…
- Conditions
- Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy
- Trial name
- NCT02994719
- Testing
- Anti-Parkinson medication, Deep Brain Stimulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Progressive Supranuclear Palsy, Brain Diseases
Personalized Parkinson Project PSP Cohort
There is an urgent need for the development of digital progression biomarkers, which are sensitive to detect small, but potentially clinically relevant changes in the disease course.
- Conditions
- Progressive Supranuclear Palsy, Brain Diseases, Neurodegenerative Diseases, Movement Disorders
- Trial name
- PPP-PSP (NCT05501431)
- Testing
- Verily Study Watch
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Progressive Supranuclear Palsy
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.
- Trial name
- NCT01110720
- Testing
- Davunetide
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 313 people
- Sponsor
- Allon Therapeutics
Progressive Supranuclear Palsy
Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
Study hypothesis: A 6-week p.o treatment with 5 mg/Kg Coenzyme Q10 is safe and tolerable,increases the brain's metabolism and ameliorates clinical symptoms in patients with PSP.
- Trial name
- NCT00328874
- Testing
- Coenzyme Q10
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- German Parkinson Study Group (GPS)
Progressive Supranuclear Palsy, PSP
AMX0035 and Progressive Supranuclear Palsy
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an…
- Conditions
- Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
- Trial name
- ORION (NCT06122662)
- Testing
- AMX0035
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 139 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Parkinson Disease, Multiple System Atrophy, Parkinson Variant
Automated Imaging Differentiation of Parkinsonism
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
- Trial name
- AIDP (NCT05913687)
- Testing
- AIDP
- Where
- 21 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- University of Florida
Progressive Supranuclear Palsy, Cognitive Impairment
Neuropsychological Evaluation for Early Diagnosis of PSP
The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.
- Trial name
- NCT03478124
- Testing
- Cognitive evaluation
- Volunteers
- 112 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Frontotemporal Dementia, Progressive Supranuclear Palsy
Study of the Neural Basis of Analogical Reasoning
Frontal patients are impaired in categorisation and analogical reasoning tasks, and different functional imaging studies from our group have shown the involvement of the prefrontal cortex in categorisation and analogy tasks.
- Conditions
- Frontotemporal Dementia, Progressive Supranuclear Palsy, Healthy Subjects
- Trial name
- ANALOG (NCT02236832)
- Testing
- transcranial magnetic stimulation, MRI imaging, EEG recording
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Progressive Supranuclear Palsy, Parkinson's Disease
Postural Instability in Progressive Supranuclear Palsy
The purpose of this study is to better understand why individuals with Progressive Supranuclear Palsy (PSP) fall. Understanding the mechanism of gait and balance dysfunction in individuals with PSP may provide us with important…
- Trial name
- NCT01563276
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Vascular Parkinsonism, Drug-induced Parkinsonism
AI-Enhanced Optimization of Acute Levodopa Challenge Test
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence.
- Conditions
- Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD)
- Trial name
- NCT06949865
- Testing
- video recording
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Tiantan Hospital
Progressive Supranuclear Palsy, Multiple System Atrophy
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design.
- Trial name
- EMERA006 (NCT04184063)
- Testing
- NBMI
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- EmeraMed
Progressive Supranuclear Palsy, Corticobasal Degeneration
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)
Treatment of tauopathies such as Progressive Supranuclear Palsy (PSP) and Cortico Basal Degeneration (CBD) remains a major challenge.
- Trial name
- APOPARKA (NCT04786158)
- Testing
- Apomorphine
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Healthy Volunteers, Alzheimer Disease
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
- Trial name
- NCT03545789
- Testing
- [18F]MNI-958
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
PSP - Progressive Supranuclear Palsy
Study Evaluating the Effect of Transcranial Direct Current Stimulation (tDCS) Targeting the Right Inferior Frontal Gyrus on Inhibitory Control in Patients With PSP
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease with a prevalence estimated at 6 per 100,000 in France and a rapidly progressive course.
- Trial name
- TinPSP (NCT07818733)
- Testing
- tDCS, or transcranial direct current stimulation
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Nantes University Hospital
Progressive Supranuclear Palsy, Dementia
Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy
to show that 1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function 2. use of rivastigmine has a positive effect on apathy in PSP patients 3.
- Trial name
- psp (NCT00522015)
- Testing
- rivastigmine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Progressive Supranuclear Palsy, Multiple System Atrophy
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
At present, the diagnosis of Parkinsons disease(PD) mainly relies on clinical symptoms and is easily confused with atypical Parkinsonian syndrome(APS) in the early stages. There is an urgent need for reliable biomarkers.
- Conditions
- Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson's Disease
- Trial name
- NCT06490926
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
The purpose of the study is to assess the safety and tolerability of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT04185415
- Testing
- bepranemab
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 25 people
- Sponsor
- UCB Biopharma SRL